Biomarkers in colorectal cancer

Anticancer Research

Volumn 36, Issue 3, 2016, Pages 1093-1102

  Yiu, Andrew J ^a   Yiu, Chu Y ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Biomarkers; Chromosome instability (CIN); Colorectal cancer; Consensus molecular subtypes; CpG island methylator phenotype (CIMP); Epidermal growth factor receptor (EGFR); Methylated DNA; MicroRNAs; Microsatellite instability (MSI); Review

Indexed keywords

BIOLOGICAL MARKER; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; MICRORNA; MICRORNA 200C; MICRORNA 224; TUMOR MARKER; UNCLASSIFIED DRUG;

BMP3 GENE; BRAF ONCOGENE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RISK; CANCER THERAPY; CANCER TISSUE; CIRCULATION; COLON CARCINOGENESIS; COLORECTAL CANCER; CONFERENCE PAPER; CPG ISLAND; DNA METHYLATION; DNA SCREENING; EPIGENETICS; FECES ANALYSIS; GENE EXPRESSION; GENE FUNCTION; GENOMICS; HUMAN; MGMT GENE; MICROARRAY ANALYSIS; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; NDRG4 GENE; ONCOGENE; OVERALL SURVIVAL; PIK3CA PROTO ONCOGENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTO ONCOGENE; PTEN GENE; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; STANDARDIZATION; TUMOR SUPPRESSOR GENE; CLINICAL TRIAL (TOPIC); COLORECTAL NEOPLASMS; EARLY CANCER DIAGNOSIS; GENETICS; MOLECULARLY TARGETED THERAPY; PERSONALIZED MEDICINE;

BIOMARKERS, TUMOR; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DNA METHYLATION; EARLY DETECTION OF CANCER; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; PRECISION MEDICINE;

EID: 84991628929     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (79)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136: E359-386, 2015.
2. Coppedè F, Lopomo A, Spisni R and Migliore L: Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. World J Gastroenterol 20: 943-956, 2014.
3. Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
4. Grady WM and Pritchard CC: Molecular alterations and biomarkers in colorectal cancer. Toxicol Pathol 42: 124-139, 2014.
5. Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L and Tejpar S: The consensus molecular subtypes of colorectal cancer. Nat Med 21: 1350-1356, 2015.
6. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS, Zhang M, Papadopoulos N, Kinzler KW, Vogelstein B, Sears CL, Anders RA, Pardoll DM and Housseau F: The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 5: 43-51, 2015.
7. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B and Diaz LA, Jr: PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med 372: 2509-2520, 2015.
8. Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandala M, Cervantes A, Arnold D and ESMO Guidelines Working Group: Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6): vi64-72, 2013.
9. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F and Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
10. Grothey A, Sargent D, Goldberg RM and Schmoll HJ: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22: 1209-1214, 2004.
11. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF and Schilsky RL: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to antiepidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27: 2091-2096, 2009.
12. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, Andre T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F and Laurent-Puig P: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26: 374-379, 2008.
13. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD and Chang DD: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634, 2008.
14. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M and Tejpar S: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11: 753-762, 2010.
15. Tejpar S and Piessevaux H: Personalized medicine in metastatic colorectal cancer treated with anti-epidermal growth factor receptor agents: a future opportunity?. Asia Pac J Clin Oncol 10(Suppl 1): 2-10, 2014.
16. Van Cutsem E, Lenz HJ, Kohne CH, Heinemann V, Tejpar S, Melezinek I, Beier F, Stroh C, Rougier P, van Krieken JH and Ciardiello F: Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 33: 692-700, 2015.
17. Tran NH, Cavalcante LL, Lubner SJ, Mulkerin DL, LoConte NK, Clipson L, Matkowskyj KA and Deming DA: Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. Ther Adv Med Oncol 7: 252-262, 2015.
18. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR and Futreal PA: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002.
19. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P and Ciardiello F: Cetuximab plus irinotecan, fluorouracil, and leucovorin as firstline treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29: 2011-2019, 2011.
20. Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002.
21. Yang ZY, Wu XY, Huang YF, Di MY, Zheng DY, Chen JZ, Ding H, Mao C and Tang JL: Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis. Int J Cancer 133: 1914-1925, 2013.
22. Huang L, Liu Z, Deng D, Tan A, Liao M, Mo Z and Yang X: Anti-epidermal growth factor receptor monoclonal antibodybased therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients. Arch Med Sci 10: 1-9, 2014.
23. Bronte G, Silvestris N, Castiglia M, Galvano A, Passiglia F, Sortino G, Cicero G, Rolfo C, Peeters M, Bazan V, Fanale D, Giordano A and Russo A: New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS?. Oncotarget 6: 24780-24796, 2015.
24. Ducasse M and Brown MA: Epigenetic aberrations and cancer. Mol Cancer 5: 60, 2006.
25. Hermann A, Gowher H and Jeltsch A: Biochemistry and biology of mammalian DNA methyltransferases. Cell Mol Life Sci 61: 2571-2587, 2004.
26. Lao VV and Grady WM: Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 8: 686-700, 2011.
27. Goel A and Boland CR: Epigenetics of colorectal cancer. Gastroenterology 143: 1442-1460. e1, 2012.
28. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB and Issa JP: CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 96: 8681-8686, 1999.
29. Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, Ahlquist DA and Berger BM: Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 370: 1287-1297, 2014.
30. Zhang H, Qi J, Wu YQ, Zhang P, Jiang J, Wang QX and Zhu YQ: Accuracy of early detection of colorectal tumours by stool methylation markers: a meta-analysis. World J Gastroenterol 20: 14040-14050, 2014.
31. Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, Castanos-Velez E, Blumenstein BA, Rosch T, Osborn N, Snover D, Day RW, Ransohoff DF and PRESEPT Clinical Study Steering Committee, Investigators and Study Team: Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 63: 317-325, 2014.
32. Pedersen SK, Baker RT, McEvoy A, Murray DH, Thomas M, Molloy PL, Mitchell S, Lockett T, Young GP and LaPointe LC: A two-gene blood test for methylated DNA sensitive for colorectal cancer. PLoS One 10: e0125041, 2015.
33. Ouchi K, Takahashi S, Yamada Y, Tsuji S, Tatsuno K, Takahashi H, Takahashi N, Takahashi M, Shimodaira H, Aburatani H and Ishioka C: DNA methylation status as a biomarker of anti-EGFR treatment for metastatic colorectal cancer. Cancer Sci 106(12): 1722-9, 2015.
34. Ebert MP, Tanzer M, Balluff B, Burgermeister E, Kretzschmar AK, Hughes DJ, Tetzner R, Lofton-Day C, Rosenberg R, Reinacher-Schick AC, Schulmann K, Tannapfel A, Hofheinz R, Rocken C, Keller G, Langer R, Specht K, Porschen R, Stohlmacher-Williams J, Schuster T, Strobel P and Schmid RM: TFAP2E-DKK4 and chemoresistance in colorectal cancer. N Engl J Med 366: 44-53, 2012.
35. Cheetham S, Tang MJ, Mesak F, Kennecke H, Owen D and Tai IT: SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-aza-2'deoxycytidine to increase SPARC expression and improve therapy response. Br J Cancer 98: 1810-1819, 2008.
36. Li Y, Lyu Z, Zhao L, Cheng H, Zhu D, Gao Y, Shang X and Shi H: Prognostic value of MGMT methylation in colorectal cancer: a meta-analysis and literature review. Tumour Biol 36: 1595-1601, 2015.
37. Kisiel JB, Yab TC, Taylor WR, Mahoney DW and Ahlquist DA: Stool methylated DNA markers decrease following colorectal cancer resection-implications for surveillance. Dig Dis Sci 59: 1764-1767, 2014.
38. Katoh H, Yamashita K, Waraya M, Margalit O, Ooki A, Tamaki H, Sakagami H, Kokubo K, Sidransky D and Watanabe M: Epigenetic silencing of HOPX promotes cancer progression in colorectal cancer. Neoplasia 14: 559-571, 2012.
39. Takahashi Y, Iwaya T, Sawada G, Kurashige J, Matsumura T, Uchi R, Ueo H, Takano Y, Eguchi H, Sudo T, Sugimachi K, Yamamoto H, Doki Y, Mori M and Mimori K: Up-regulation of NEK2 by microRNA-128 methylation is associated with poor prognosis in colorectal cancer. Ann Surg Oncol 21: 205-212, 2014.
40. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
41. Lin S and Gregory RI: MicroRNA biogenesis pathways in cancer. Nat Rev Cancer 15: 321-333, 2015.
42. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH and Kim VN: MicroRNA genes are transcribed by RNA polymerase II. EMBO J 23: 4051-4060, 2004.
43. Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, Cooch N and Shiekhattar R: The Microprocessor complex mediates the genesis of microRNAs. Nature 432: 235-240, 2004.
44. Denli AM, Tops BB, Plasterk RH, Ketting RF and Hannon GJ: Processing of primary microRNAs by the Microprocessor complex. Nature 432: 231-235, 2004.
45. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S and Kim VN: The nuclear RNase III Drosha initiates microRNA processing. Nature 425: 415-419, 2003.
46. Han J, Lee Y, Yeom KH, Kim YK, Jin H and Kim VN: The DROSHA-DGCR8 complex in primary microRNA processing. Genes Dev 18: 3016-3027, 2004.
47. Bohnsack MT, Czaplinski K and Gorlich D: Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 10: 185-191, 2004.
48. Iorio MV and Croce CM: MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 4: 143-159, 2012.
49. Park JE, Heo I, Tian Y, Simanshu DK, Chang H, Jee D, Patel DJ and Kim VN: Dicer recognizes the 5' end of RNA for efficient and accurate processing. Nature 475: 201-205, 2011.
50. Bhayani MK, Calin GA and Lai SY: Functional relevance of miRNA sequences in human disease. Mutat Res 731: 14-19, 2012.
51. Sun W, Julie Li YS, Huang HD, Shyy JY and Chien S: microRNA: a master regulator of cellular processes for bioengineering systems. Annu Rev Biomed Eng 12: 1-27, 2010.
52. Hollis M, Nair K, Vyas A, Chaturvedi LS, Gambhir S and Vyas D: MicroRNAs potential utility in colon cancer: Early detection, prognosis, and chemosensitivity. World J Gastroenterol 21: 8284-8292, 2015.
53. Ma L, Teruya-Feldstein J and Weinberg RA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449: 682-688, 2007.
54. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M and Croce CM: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101: 2999-3004, 2004.
55. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB and Tewari M: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105: 10513-10518, 2008.
56. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J and Zhang CY: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997-1006, 2008.
57. Xuan Y, Yang H, Zhao L, Lau WB, Lau B, Ren N, Hu Y, Yi T, Zhao X, Zhou S and Wei Y: MicroRNAs in colorectal cancer: small molecules with big functions. Cancer Lett 360: 89-105, 2015.
58. Liu GH, Zhou ZG, Chen R, Wang MJ, Zhou B, Li Y and Sun XF: Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumour Biol 34: 2175-2181, 2013.
59. Wu CW, Ng SS, Dong YJ, Ng SC, Leung WW, Lee CW, Wong YN, Chan FK, Yu J and Sung JJ: Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut 61: 739-745, 2012.
60. Kanaan Z, Rai SN, Eichenberger MR, Roberts H, Keskey B, Pan J and Galandiuk S: Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg 256: 544-551, 2012.
61. Kanaan Z, Roberts H, Eichenberger MR, Billeter A, Ocheretner G, Pan J, Rai SN, Jorden J, Williford A and Galandiuk S: A plasma microRNA panel for detection of colorectal adenomas: a step toward more precise screening for colorectal cancer. Ann Surg 258: 400-408, 2013.
62. Wu CW, Ng SC, Dong Y, Tian L, Ng SS, Leung WW, Law WT, Yau TO, Chan FK, Sung JJ and Yu J: Identification of microRNA-135b in stool as a potential noninvasive biomarker for colorectal cancer and adenoma. Clin Cancer Res 20: 2994-3002, 2014.
63. Koga Y, Yamazaki N, Yamamoto Y, Yamamoto S, Saito N, Kakugawa Y, Otake Y, Matsumoto M and Matsumura Y: Fecal miR-106a is a useful marker for colorectal cancer patients with false-negative results in immunochemical fecal occult blood test. Cancer Epidemiol Biomarkers Prev 22: 1844-1852, 2013.
64. Ahmed FE, Ahmed NC, Vos PW, Bonnerup C, Atkins JN, Casey M, Nuovo GJ, Naziri W, Wiley JE, Mota H and Allison RR: Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle. Cancer Genomics Proteomics 10: 93-113, 2013.
65. Mlcochova J, Faltejskova-Vychytilova P, Ferracin M, Zagatti B, Radova L, Svoboda M, Nemecek R, John S, Kiss I, Vyzula R, Negrini M and Slaby O: MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab. Oncotarget 17; 6(36): 38695-704, 2015.
66. Simmer F, Venderbosch S, Dijkstra JR, Vink-Borger EM, Faber C, Mekenkamp LJ, Koopman M, De Haan AF, Punt CJ and Nagtegaal ID: MicroRNA-143 is a putative predictive factor for the response to fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer. Oncotarget 6: 22996-23007, 2015.
67. Perez-Carbonell L, Sinicrope FA, Alberts SR, Oberg AL, Balaguer F, Castells A, Boland CR and Goel A: miR-320e is a novel prognostic biomarker in colorectal cancer. Br J Cancer 113: 83-90, 2015.
68. Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland R, Goel A: Serum miRNA-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg 259(4): 735-743, 2014.
69. Ling H, Pickard K, Ivan C, Isella C, Ikuo M, Mitter R, Spizzo R, Bullock MD, Braicu C, Pileczki V, Vincent K, Pichler M, Stiegelbauer V, Hoefler G, Almeida MI, Hsiao A, Zhang X, Primrose JN, Packham GK, Liu K, Bojja K, Gafa R, Xiao L, Rossi S, Song JH, Vannini I, Fanini F, Kopetz S, Zweidler-McKay P, Wang X, Ionescu C, Irimie A, Fabbri M, Lanza G, Hamilton SR, Berindan-Neagoe I, Medico E, Mirnezami AH, Calin GA and Nicoloso MS: The clinical and biological significance of miR-224 expression in colorectal cancer metastasis. Gut 0: 1-13 doi:10. 1136/gutjnl-2015-309372, 2015.
70. Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337, 2012.
71. Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH and Xu RH: Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology 60: 598-609, 2014.
72. Liu H, Du L, Wen Z, Yang Y, Li J, Wang L, Zhang X, Liu Y, Dong Z, Li W, Zheng G and Wang C: Up-regulation of miR-182 expression in colorectal cancer tissues and its prognostic value. Int J Colorectal Dis 28: 697-703, 2013.
73. Wang MJ, Li Y, Wang R, Wang C, Yu YY, Yang L, Zhang Y, Zhou B, Zhou ZG and Sun XF: Down-regulation of microRNA-124 is an independent prognostic factor in patients with colorectal cancer. Int J Colorectal Dis 28: 183-189, 2013.
74. Liao WT, Ye YP, Zhang NJ, Li TT, Wang SY, Cui YM, Qi L, Wu P, Jiao HL, Xie YJ, Zhang C, Wang JX and Ding YQ: MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2. J Pathol 232: 415-427, 2014.
75. Lou X, Qi X, Zhang Y, Long H and Yang J: Decreased expression of microRNA-625 is associated with tumor metastasis and poor prognosis in patients with colorectal cancer. J Surg Oncol 108: 230-235, 2013.
76. Stiegelbauer V, Perakis S, Deutsch A, Ling H, Gerger A and Pichler M: MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer. World J Gastroenterol 20: 11727-11735, 2014.
77. Ren A, Dong Y, Tsoi H and Yu J: Detection of miRNA as noninvasive biomarkers of colorectal cancer. Int J Mol Sci 16: 2810-2823, 2015.
78. Hu J, Wang Z, Liao BY, Yu L, Gao X, Lu S, Wang S, Dai Z, Zhang X, Chen Q, Qiu SJ, Wu Y, Zhu H, Fan J, Zhou J and Wang J: Human miR-1228 as a stable endogenous control for the quantification of circulating microRNAs in cancer patients. Int J Cancer 135: 1187-1194, 2014.
79. Hamm A, Prenen H, Van Delm W, Di Matteo M, Wenes M, Delamarre E, Schmidt T, Weitz J, Sarmiento R, Dezi A, Gasparini G, Rothe F, Schmitz R, D'Hoore A, Iserentant H, Hendlisz A and Mazzone M: Tumour-educated circulating monocytes are powerful candidate biomarkers for diagnosis and disease follow-up of colorectal cancer. Gut 0: 1-11. doi: 10. 1136/gutjnl-2014-308988, 2015.